Radiotherapy in the treatment of Hodgkin’s lymphoma

Abstract

Hodgkin’s lymphoma (HL) is a very radiosensitive and chemosensitive neoplasm. Approximately 90% of patients with early-stage HL can be cured with standard chemotherapy, radiation or combined modalities. Excellent treatment outcomes resulted in searching for equally effective but less toxic therapies. Speaking about radiotherapy it meant changing the irradiated tissue volumes and/or decreasing the total dose. Here we discuss current indications for radiotherapy and principles of treatment planning.